BioCentury
ARTICLE | Company News

Laekna gets rights to Novartis cancer candidates

August 3, 2018 5:52 PM UTC

Laekna Therapeutics Shanghai Co. Ltd. (Shanghai, China) acquired exclusive, worldwide rights to develop and commercialize two clinical stage cancer compounds from Novartis AG (NYSE:NVS; SIX:NOVN).

The pharma will take an equity stake in Laekna, which will also receive an upfront payment and is eligible for milestones and royalties. Novartis told BioCentury that financial terms are undisclosed...